EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE     

Skip to content

en English
hy Armenianhr Croatiancs Czechda Danishnl Dutchen Englishfi Finnishfr Frenchde Germanel Greekiw Hebrewhu Hungarianis Icelandicit Italianlv Latvianlt Lithuanianmk Macedonianno Norwegianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishtr Turkish

Myeloma Patients EuropeMyeloma Patients Europe
Search:
  • About us
  • Contact us
  • en English
    hy Armenianhr Croatiancs Czechda Danishnl Dutchen Englishfi Finnishfr Frenchde Germanel Greekiw Hebrewhu Hungarianis Icelandicit Italianlv Latvianlt Lithuanianmk Macedonianno Norwegianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishtr Turkish
Superior MPE
Myeloma Patients Europe
Myeloma Patients EuropeMyeloma Patients Europe
  • Myeloma and AL Amyloidosis
    • About Multiple Myeloma
    • About AL amyloidosis
  • What we do
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
      • COVID-19
    • Research
      • Patient Evidence
      • Horizon Europe
      • IMI
    • Access
      • Access to myeloma treatment
      • CEE workgroup on Access
      • Myeloma Trial Navigator
  • Educational resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Conference reports
    • Guides
  • European Myeloma Day
  • News

Privacy Policy

Cookies Policy

Facebook page opens in new windowTwitter page opens in new windowYouTube page opens in new windowLinkedin page opens in new window

EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE

  • About MPE
    • Our members
    • Our board and staff
    • Medical Advisory Commitee
    • Our funding
    • Get involved in MPE activities
    • Become a MPE member
  • Contact us
  • Myeloma and AL Amyloidosis
    • About myeloma
      • What is myeloma?
      • What causes myeloma?
      • Coping with a myeloma diagnosis
      • Early diagnosis and smoldering myeloma
      • Diagnostic tests
      • Treatment of myeloma
      • Myeloma symptoms and treatment side-effects
      • Caring for yourself
      • Dealing with the psycho-social aspects of the disease
      • Managing myeloma and work, finance and advance decisions
      • Myeloma landscape and future directions
      • Clinical trials
      • Finding out about myeloma clinical trials
    • About AL amyloidosis
      • What are the main AL amyloidosis treatments?
      • How is AL amyloidosis diagnosed?
      • What is the relation between AL amyloidosis and myeloma?
  • What we do
    • Member and patient community programmes
      • MPE Masterclass
      • Scholarship programme
      • Myeloma CABs
      • MPE Myeloma and AL amyloidosis Community Taskforce
      • Advocate Development Programme
      • COVID-19
      • Reasonable Agreements between Patient Advocates and Pharmaceutical Companies (RAPP)
    • Research
      • Patient Evidence
      • Horizon Europe
        • MMPredict
        • CARAMBA
      • IMI
        • Harmony
        • Sisaqol
    • Access
      • Access to myeloma treatment
      • CEE workgroup on Access
      • Myeloma and AL Amyloidosis Trial Navigator
  • Educational resources
    • Educational clips
    • Webinars
    • Q&As
    • Toolkits
    • Factsheets
    • Conference reports
    • Guides
  • News
  • European Myeloma Day
    • Myeloma infographics
    • AL amyloidosis infographics
    • Videos

CEE workgroup

You are here:
  1. Home
  2. CEE workgroup
Go to Top

  • This field is for validation purposes and should be left unchanged.